Tianjin Chase Sun Pharmaceutical Co Ltd (300026) — Cash Flow Reinvestment Rate
Tianjin Chase Sun Pharmaceutical Co Ltd (300026) has a Cash Flow Reinvestment Rate of 0.14x as of September 2025, reinvesting CN¥21.58 Million (capex CN¥21.58 Million ) from operating cash flow of CN¥153.30 Million. See 300026 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Tianjin Chase Sun Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2006–2024)
Historical reinvestment intensity for Tianjin Chase Sun Pharmaceutical Co Ltd across 19 annual periods. For the full cash flow conversion analysis, see Tianjin Chase Sun Pharmaceutical Co Ltd cash flow conversion.
Annual Cash Flow Reinvestment Rate for Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2024)
Year-by-year capital reinvestment analysis for Tianjin Chase Sun Pharmaceutical Co Ltd. See financial flexibility index of Tianjin Chase Sun Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.23x | CN¥199.91 Million | CN¥852.24 Million | CN¥193.12 Million | ▼ -52.1% |
| 2023 | 0.49x | CN¥750.04 Million | CN¥1.53 Billion | CN¥347.12 Million | ▼ -75.6% |
| 2022 | 2.01x | CN¥1.50 Billion | CN¥745.35 Million | CN¥770.27 Million | ▲ +13.8% |
| 2021 | 1.77x | CN¥692.19 Million | CN¥391.60 Million | CN¥677.45 Million | ▼ -38.7% |
| 2020 | 2.88x | CN¥566.93 Million | CN¥196.66 Million | CN¥563.78 Million | ▼ -5.9% |
| 2019 | 3.06x | CN¥662.25 Million | CN¥216.10 Million | CN¥591.01 Million | ▲ +302.4% |
| 2018 | 0.76x | CN¥295.61 Million | CN¥388.19 Million | CN¥294.89 Million | ▲ +13.6% |
| 2017 | 0.67x | CN¥497.73 Million | CN¥742.38 Million | CN¥383.34 Million | ▼ -70.6% |
| 2016 | 2.28x | CN¥1.02 Billion | CN¥448.08 Million | CN¥415.52 Million | ▲ +1.9% |
| 2015 | 2.24x | CN¥270.51 Million | CN¥121.00 Million | CN¥223.35 Million | ▲ +87.9% |
| 2014 | 1.19x | CN¥178.37 Million | CN¥149.94 Million | CN¥178.37 Million | ▲ +59.4% |
| 2013 | 0.75x | CN¥107.20 Million | CN¥143.60 Million | CN¥107.20 Million | ▼ -48.6% |
| 2012 | 1.45x | CN¥221.17 Million | CN¥152.21 Million | CN¥221.17 Million | ▼ -80.3% |
| 2011 | 7.37x | CN¥262.51 Million | CN¥35.64 Million | CN¥262.51 Million | ▲ +201.7% |
| 2010 | 2.44x | CN¥112.90 Million | CN¥46.25 Million | CN¥112.90 Million | ▲ +561.8% |
| 2009 | 0.37x | CN¥49.82 Million | CN¥135.06 Million | CN¥49.82 Million | ▼ -40.6% |
| 2008 | 0.62x | CN¥48.28 Million | CN¥77.74 Million | CN¥48.28 Million | ▲ +661.3% |
| 2007 | 0.08x | CN¥5.87 Million | CN¥72.01 Million | CN¥5.87 Million | ▼ -96.8% |
| 2006 | 2.54x | CN¥3.12 Million | CN¥1.22 Million | CN¥3.12 Million | — |